Abstract
Background Medication non-adherence may lead to poor therapeutic outcomes. Cognitive functions deteriorate with age, contributing to decreased adherence. Interventions have been tested to improve adherence in seniors with cognitive impairment or Alzheimer disease (AD), but high-quality systematic reviews are lacking. It remains unclear which interventions are promising. Objectives We conducted a systematic review to identify, describe, and evaluate interventions aimed at improving medication adherence among seniors with any type of cognitive impairment. Methods Following NICE guidance, databases and websites were searched using combinations of controlled and free vocabulary. All adherence-enhancing interventions and study designs were considered. Studies had to include community dwelling seniors, aged 65 years or older, with cognitive impairment, receiving at least one medication for a chronic condition, and an adherence measure. Study characteristics and methodological quality were assessed. Results We identified 13 interventions, including six RCTs. Two studies were of poor, nine of low/medium and two of high quality. Seven studies had sample sizes below 50 and six interventions focused on adherence to AD medication. Six interventions tested a behavioral, four a medication oriented, two an educational and one a multi-faceted approach. Studies rarely assessed therapeutic outcomes. All but one intervention showed improved adherence. Conclusion Three medium quality studies showed better adherence with patches than with pills for AD treatment. Promising interventions used educational or reminding strategies, including one high quality RCT. Nine studies were of low/moderate quality. High quality RCTs using a theoretical framework for intervention selection are needed to identify strategies for improved adherence in these seniors.
Similar content being viewed by others
References
Ramage-Morin PL. Medication use among senior Canadians. Health Rep. 2009;20:37–44.
Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2012. Ottawa, ON. May 2014.
National Center for Health Statistics. Health, United States, 2014: In Brief. Hyattsville, MD2014. DHHS Publication No. 2015–1210.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppart T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.
Kröger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27:663–75.
Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
Perreault S, Ellia L, Dragomir A, Cote R, Blais L, Berard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122:647–55.
Perreault S, Yu AY, Cote R, Dragomir A, White-Guay B, Dumas S. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43.
Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81.
Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943–51.
Arlt S, Lindner R, Rosler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033–47.
Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275:214–28.
Tuokko H, Morris C, Ebert P. Mild cognitive impairment and everyday functioning in older adults. Neurocase. 2005;11:40–7.
Panza F, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry. 2005;13:633–44.
Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793–6.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.
Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement J Alzheimers Assoc. 2012;8:14–21.
Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312:2551–61.
Bickel H, Mosch E, Seigerschmidt E, Siemen M, Forstl H. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dement Geriatr Cogn Disord. 2006;21:242–50.
Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252–65.
Alzheimer’s Disease International, Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London, UK, August 2015.
Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol. 2001;57:589–94.
Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.
Luzny J, Ivanova K, Jurickova L. Non-adherence in seniors with dementia—a serious problem of routine clinical practice. Acta Med (Hradec Kralove). 2014;57:73–7.
Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.
Van Eijken M, Tsang S, Wensing M, De Smet PAGM, Grol RPTM. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging. 2003;20:229–40.
Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30:33–43.
George J, Elliott RA, Stewart DC. A systematic review of interventions to improve medication taking in elderly patients prescribed multiple medications. Drugs Aging. 2008;25:307–24.
Banning M. A review of interventions used to improve adherence to medication in older people. Int J Nurs Stud. 2009;46:1505–15.
Conn VS, Hafdahl AR, Cooper PS, Ruppar TM, Mehr DR, Russell CL. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials. Gerontologist. 2009;49:447–62.
Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10:165–77.
Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59:624–31.
Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from www.handbook.cochrane.org.
National Institute for Health and Care Excellence. Methods for the development of NICE public health guidance. 3rd ed. London: National Institute for Health and Care Excellence; 2012. https://www.nice.org.uk/process/pmg4/chapter/appendix-f-quality-appraisal-checklist-quantitative-intervention-studies.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20:267–78.
van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55.
Hawkins LA, Firek CJ. Testing a novel pictorial medication sheet to improve adherence in veterans with heart failure and cognitive impairment. Heart Lung J Crit Care. 2014;43:486–93.
Insel KC, Cole L. Individualizing memory strategies to improve medication adherence. Appl Nurs Res. 2005;18:199–204.
Kripalani S, Schmotzer B, Jacobson TA. Improving medication adherence through graphically enhanced interventions in coronary heart disease (IMAGE-CHD): a randomized controlled trial. J Gen Intern Med. 2012;27:1609–17.
Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563–71.
Leirer VO, Morrow DG, Tanke ED, Pariante GM. Elders’ nonadherence: its assessment and medication reminding by voice mail. Gerontologist. 1991;31:514–20.
Ownby RL, Hertzog C, Czaja SJ. Tailored information and automated reminding to improve medication adherence in Spanish- and English-speaking elders treated for memory impairment. Clin Gerontol. 2012;35:221–38.
Smith GE, Lunde AM, Hathaway JC, Vickers KS. Telehealth home monitoring of solitary persons with mild dementia. Am J Alzheimer’s Dis Other Dement. 2007;22:20–6.
Tian H, Abouzaid S, Chen W, Kahler KH, Kim E. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord. 2013;27:182–6.
Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract. 2014;68:465–70.
Oswald WD, Gunzelmann T, Wannenmacher W. Die Compliance von Patienten höheren Lebensalters mit Hirnleistungsstörungen bei Encephabol forte und Encephabol 600 [Compliance of patients with dementia syndrome treated with Encephabol forte and Encephabol 600]. Z Gerontopsychologie Psychiatr. 1993;6:17–25.
Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease. Expert Rev Neurother. 2012;12:31–7.
Kamimura T, Ishiwata R, Inoue T. Medication reminder device for the elderly patients with mild cognitive impairment. Am J Alzheimer’s Dis Other Dement. 2012;27:238–42.
Watanabe N, Yamamura K, Suzuki Y, Umegaki H, Shigeno K, Matsushita R, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605–11.
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.
Folstein MF, Folstein SE, McHugh PR. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Tariq SH, Tumosa N, Chibnall JT, Perry MH 3rd, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. Am J Geriatr Psychiatry. 2006;14:900–10.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.
Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006; CD005593.
Kröger E, Mouls M, Wilchesky M, Berkers M, Carmichael PH, van Marum R, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. Ann Pharmacother. 2015;31:1197–206.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
Khan KS, Dinnes J, Kleijnen J. Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol. 2001;95:6–11.
Popay J, Roberts H, Sowden A, Petticrew M, Arai Y, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. 1st ed. Lancaster: Institute for Health Research, Bowland Tower East Wing, Lancaster University; 2006.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16:CD000011.
Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36:26–9.
Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014;201:390–2.
Reeve E, Turner JP. Patients’ perspectives on the brave new word ‘deprescribing’. Int J Pharm Pract. 2015;23:90–1.
Acknowledgements
The authors wish to thank the research professionals who worked on this review, Ms Martine Marcotte and Ms Laura Finken, as well as a resident in geriatric medicine who participated in the article selection, Dr Pierre Molin. They also wish to thank Dr. André Tourigny from the CEVQ who was instrumental in initiating this research, and Ms Zorica Djordjevic, librarian at the Hôpital St-Sacrement du CHU de Québec, who contributed to the database search strategy.
Funding
Chair on adherence to treatments, Université Laval (EKröger) and from the Centre d’excellence sur le vieillissement de Québec (CEVQ) and the Réseau québécois de recherche sur le vieillissement du Fonds de recherche du Québec—santé (E Kröger)
Conflicts of interest
None of the authors have any conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Appendix 1
See Table 4.
Appendix 2: PubMed search strategy
-
1.
(“Patient compliance”[Mesh] OR “compliance”[TiAb] OR “compliant”[TiAb] OR “adherence”[TiAb] OR “adherent”[TiAb] OR “persistence”[TiAb] OR “persistent”[TiAb] OR “appropriate use”[TiAb] OR “concordance”[TiAb] OR “patient cooperation”[TiAb] OR “Medication therapy management”[Mesh] OR “drug therapy management”[TiAb] OR “therapy management”[TiAb] OR “treatment management”[TiAb] OR “medication management”[TiAb] OR “self-management”[TiAb] OR “patient education”[TiAb] OR “Treatment refusal”[Mesh] OR “treatment refusal”[TiAb] OR “refusal of treatment”[TiAb] OR “Patient dropouts”[Mesh] OR “Patient dropout*”[TiAb] OR “Treatment dropout*”[TiAb] OR “dropouts”[TiAb] OR “dropout”[TiAb] OR “Prescription Drug Misuse”[Mesh] OR “Self administration”[Mesh])
-
2.
(“Cognition disorders”[Mesh] OR “impaired cognition”[TiAb] OR “impaired function”[TiAb] OR “impaired memory”[TiAb] OR “function impairment”[TiAb] OR “functional impairment”[TiAb] OR “memory impairment”[TiAb] OR “cognitive loss”[TiAb] OR “cognitive dysfunction”[TiAb] OR “cognitive deficit”[TiAb] OR “cognitive decline”[TiAb] OR “cognitive defect”[TiAb] OR “cognitive problems”[TiAb] OR “memory dysfunction”[TiAb] OR “memory loss”[TiAb] OR “memory deficit”[TiAb] OR “memory decline”[TiAb] OR “memory defect”[TiAb] OR “memory problems”[TiAb] OR “cognitive abilities”[TiAb] OR “executive function”[TiAb] OR “cognitively impaired”[TiAb] OR “Cognitive impairment”[TiAb] OR “cognitive disorder”[TiAb] OR “Dementia””[Mesh])
-
3.
#1 AND #2
Filters activated: Humans, English, French, German, Aged: 65+ years.
Rights and permissions
About this article
Cite this article
Kröger, E., Tatar, O., Vedel, I. et al. Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions. Int J Clin Pharm 39, 641–656 (2017). https://doi.org/10.1007/s11096-017-0487-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-017-0487-6